Last Price
4.37
Today's Change
+0.01 (0.22%)
Day's Change
4.32 - 4.46
Trading Volume
31,886
Profile
DMAC
Exchange: NASDAQ Capital Market NASDAQ Capital Market
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Mr. Dietrich John Pauls MBA Mr. Dietrich John Pauls MBA
Full Time Employees: 18 18
IPO Date: 2012-08-03 2012-08-03
CIK: 0001401040 0001401040
ISIN: CA25253X2077 CA25253X2077
CUSIP: 25253X207 25253X207
Beta: 1.48 1.48
Last Dividend: 0.00 0.00
Dcf Diff: 4.28 4.28
Dcf: 0.13 0.13
Description
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Address
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Featured Posts
12
Apps
Top Articles
1
CEO Morning Brief
2
CEO Morning Brief
3
CEO Morning Brief
4
5
CEO Morning Brief
OpenAI Lets Anyone Use Its New Voice Assistant in Third-party Apps
#
Stock
Score
Daily Stocks
Stock
Last
Change
Volume
Stock
Last
Change
Volume
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
